01 9Spiriva
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,136
2019 Revenue in Millions : 2,451
Growth (%) : -13
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,704
2020 Revenue in Millions : 2,136
Growth (%) : -14
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 1,691
2021 Revenue in Millions : 1,704
Growth (%) : -1
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 1,373
2022 Revenue in Millions : 1,691
Growth (%) : -17
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 1,202
2023 Revenue in Millions : 1,398
Growth (%) : -14
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 3,175
2015 Revenue in Millions : 3,766
Growth (%) : -16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 2,726
2017 Revenue in Millions : 3,196
Growth (%) : -15%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 2,243
2018 Revenue in Millions : 2,629
Growth (%) : -15
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : -9%
2013 Revenue in Millions :
Growth (%) :
